Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

Would patients receiving targeted therapies be eligible for TTFields for brain metastases?

3
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Florida International University

Conceptually, I can certainly hypothesize and conjecture the value of combining TTFields for brain metastases with targeted therapies. However, this specific population was excluded from the current trial, and therefore, we have no direct data to report or answer this question with greater specifi...

Are there any radiation dosimetric considerations for patients with lung cancer that have had a TAVR?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Texas at Tyler

No, the new valve solves a mechanical problem. It will have some metal in it, so it would be visible whether it is a mechanical or biosynthetic type. I'd suggest not having a direct beam hit it, as that is the area of the coronary arteries' origins, and avoid dose spillage to reduce late toxicity. T...

Would you give adjuvant radiation after complete resection of a small primary cutaneous follicular lymphoma of the scalp?

5
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

Not a lot of data, but here goes. First, one has to go back decades in the literature to find series of patients with lymphoma rx'd with surgical resection alone. In general addition of RT improved outcome even when ostensibly resected with neg margins. With today's technology risk of additional RT ...

What criteria do you use in deciding whether or not to treat the pelvis in prostate cancer?

15
6 Answers

Mednet Member
Mednet Member
Radiation Oncology · Case Western Reserve University/ University Hospitals Seidman Cancer Center

NRG/RTOG 0924 - The end of elective nodal RT in localized prostate cancer? Top line results: NRG/RTOG 0924 is a very large phase III randomized trial powered for overall survival (OS) to determine if there is a benefit of the addition of whole pelvic radiotherapy (WPRT) to prostate RT plus ADT. This...

For patients undergoing bladder preservation therapy with trimodal therapy, how do you manage the urinary urgency and frequency during and after treatment?

3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Virginia Commonwealth University Medical Center

This can be a difficult problem to manage because I try to avoid treatment interruption if at all possible, which is different from my approach in patients with prostate cancer, where treatment interruption is a safe and effective alternative. In patients with bladder cancer, the first thing I will ...

In patients with iron deficiency due to history of gastric bypass or IBD, would you consider oral iron therapy if the iron deficiency anemia is mild?

1
5 Answers

Mednet Member
Mednet Member
Hematology · Gundersen Health

Oral iron can often be effective in iron deficiency, as long as absorption is intact. If you are concerned about absorption, performing an oral iron challenge can be useful in allowing you to avoid long trials of oral iron that will be ineffective. Simply check an iron panel at baseline, then admini...

What would be your radiotherapy plan for a patient with recurrent GBM (WHO grade 4, IDH wild-type) s/p 2 prior resections with no prior radiation?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Arizona

The scenario described in this clinical case is not uncommon. I have had patients who either live several hours away from our center or were unwilling to receive the Stupp protocol of 60 Gy in 6 weeks and were successfully treated with 3 weeks of hypofractionated RT (HFRT). HFRT over 1–3 weeks (25 G...

Should we consider deferring adjuvant chemotherapy for resected early-stage NSCLC in light of COVID-19?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Indiana University School of Medicine

This is a great and timely question! The absolute benefit observed with adjuvant chemotherapy in surgically resected NSCLC is greatest in those patients with stage II and III disease. The question is how long can one wait to give adjuvant chemotherapy and maintain its benefits. Salazar and colleague...

Do you still recommend protons for grade 2 and grade 3 glioma, following the Soprano study results showing a survival detriment?

2
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Icahn School of Medicine at Mount Sinai

I should start by saying that I generally do not recommend proton therapy for grade 2-3 gliomas in adults unless there is a clear and specific indication. Modern photon techniques such as VMAT are highly conformal, efficient, and safe, and they form the backbone of the evidence base that guides our ...

What are best practices for dermatologists and oncologists to collaborate in order to optimize multidisciplinary care of patients with high risk CSCC?

3
3 Answers

Mednet Member
Mednet Member
Dermatology · University of Pennsylvania

A network of specialists familiar with cSCC is necessary to optimize care that is tailored and appropriate for each unique case. Avoiding under-treatment and over-treatment is important, but also challenging, given the high volume of cSCC tumors with variable patterns of presentation and numerous cr...